Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis

Deucravacitinib was significantly more effective than placebo in the 52-week, phase III POETYK PSO-1 and PSO-2 trials. This study further evaluated deucravacitinib efficacy compared with placebo in these trials based on Psoriasis Area and Severity Index (PASI) outcomes. Patients with moderate to severe plaque psoriasis received placebo or deucravacitinib 6 mg once daily. At week 16, patients crossed over from placebo to deucravacitinib. Patients treated with deucravacitinib had greater reductions from baseline in PASI within 1 week, with higher improvements observed compared with placebo at week 16. Patients who crossed over to deucravacitinib at week 16 achieved similar improvements at week 52 as patients treated continuously with deucravacitinib from day 1. Significantly higher proportions of patients treated with deucravacitinib achieved treat-to-target PASI thresholds (≤ 1, ≤ 2, ≤ 3, ≤ 4, ≤ 5), and significantly greater improvements were observed in each PASI component (body region: head, trunk, upper/lower extremities; plaque characteristics: erythema, induration, desquamation) compared with placebo at week 16.

Authors

Institutions

Publication Details

Journal
Clinical and Experimental Dermatology
Published
2025-05-24
DOI
https://doi.org/10.1093/ced/llaf215
Citations
1
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.80

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis

Peter Foley, Melinda Gooderham, Misti Linaberry, Mark Lebwohl et al.
1 citations
Clinical and Experimental Dermatology
Psoriasis: Treatment and Pathogenesis
0.80
article

Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis

Peter Foley, Melinda Gooderham, Misti Linaberry, Mark Lebwohl, Alice Bendix Gottlieb, Tiago Torres, Christopher E.M. Griffiths, Ying-Ming Jou, Carolin Daamen, Richard Bruce Warren, Diamant Thaçi, Zoran Popmihajlov
article en
1 citations

Abstract

Deucravacitinib was significantly more effective than placebo in the 52-week, phase III POETYK PSO-1 and PSO-2 trials. This study further evaluated deucravacitinib efficacy compared with placebo in these trials based on Psoriasis Area and Severity Index (PASI) outcomes. Patients with moderate to severe plaque psoriasis received placebo or deucravacitinib 6 mg once daily. At week 16, patients crossed over from placebo to deucravacitinib. Patients treated with deucravacitinib had greater reductions from baseline in PASI within 1 week, with higher improvements observed compared with placebo at week 16. Patients who crossed over to deucravacitinib at week 16 achieved similar improvements at week 52 as patients treated continuously with deucravacitinib from day 1. Significantly higher proportions of patients treated with deucravacitinib achieved treat-to-target PASI thresholds (≤ 1, ≤ 2, ≤ 3, ≤ 4, ≤ 5), and significantly greater improvements were observed in each PASI component (body region: head, trunk, upper/lower extremities; plaque characteristics: erythema, induration, desquamation) compared with placebo at week 16.

Clinical and Experimental DermatologyVol. 50(10)
The University of Melbourne (AU), Universidade do Porto (PT), King's College London (GB), Queen's University (CA), Manchester Academic Health Science Centre (GB), Northern Health and Social Care Trust (GB), St Vincent's Hospital Melbourne (AU), Bristol-Myers Squibb (United States) (US), The Catholic University of Korea St. Vincent's Hospital (KR), Manchester University NHS Foundation Trust (GB), Probity Medical Research (CA), Bristol-Myers Squibb (Sweden) (SE), King's College Hospital (GB), Centro Hospitalar do Porto (PT), NIHR Manchester Biomedical Research Centre (GB), Skin Health Institute (AU), University of Lübeck (DE), Icahn School of Medicine at Mount Sinai (US)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Sanofi, Teva Pharmaceutical Industries, Celgene, XBiotech, Celltrion, National Institute for Health and Care Research, Sun Pharma, LEO Pharma, Samsung, Manchester Biomedical Research Centre
Good health and well-being
Openalex Percentile: Top 28%
Psoriasis: Treatment and Pathogenesis
0.80
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.